Search
BPR-0L075
go.drugbank.com/drugs/DB17155InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesEP-0042
go.drugbank.com/drugs/DB18120InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesFerroheme
go.drugbank.com/drugs/DB18267InvestigationalCategories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsFenvalerate
go.drugbank.com/drugs/DB18391ExperimentalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsCrinecerfont
go.drugbank.com/drugs/DB18518ApprovedInvestigationalPatients with congenital adrenal hyperplasia (CAH) face two major problems: adrenal insufficiency, caused by insufficient endogenous cortisol production, and androgen excess, caused by a counter-regulatory overproduction of adrenocortico...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesBefotertinib
go.drugbank.com/drugs/DB18844InvestigationalBefotertinib is under investigation in clinical trial NCT05007938 (Befotertinib and Icotinib in Treatment-naive Patients With Advanced Egfr-mutant Lung Cancer).
Categories: P-glycoprotein inhibitorsAvenciguat
go.drugbank.com/drugs/DB18882InvestigationalAvenciguat is under investigation in clinical trial NCT05282121 (A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (N...
Categories: P-glycoprotein substratesEpaminurad
go.drugbank.com/drugs/DB18973InvestigationalEpaminurad is under investigation in clinical trial NCT05815901 (A Therapeutic Confirmatory Study of Epaminurad Versus Febuxostat in Gout Patients).
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesBersacapavir
go.drugbank.com/drugs/DB19035InvestigationalBersacapavir is under investigation in clinical trial NCT03365947 (Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)).
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 SubstratesImlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalImlunestrant is a brain-penetrant selective estrogen receptor antagonist and degrader. The FDA approved imlunestrant on September 25, 2025 as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-muta...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 Substrates